TOI Stock - The Oncology Institute, Inc.
Unlock GoAI Insights for TOI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $393.41M | $324.24M | $252.48M | $203.00M | $187.51M |
| Gross Profit | $54.00M | $59.57M | $52.09M | $40.85M | $36.88M |
| Gross Margin | 13.7% | 18.4% | 20.6% | 20.1% | 19.7% |
| Operating Income | $-60,118,000 | $-77,018,000 | $-81,951,000 | $-45,858,000 | $-8,195,903 |
| Net Income | $-64,663,000 | $-83,068,000 | $152,000 | $-10,927,000 | $-14,321,235 |
| Net Margin | -16.4% | -25.6% | 0.1% | -5.4% | -7.6% |
| EPS | $-0.71 | $-0.92 | $0.00 | $-0.16 | $-0.24 |
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | Needham | Initiation | Buy | $5 |
| July 23rd 2025 | Noble Capital Markets | Initiation | Outperform | $8 |
| July 16th 2025 | B. Riley Securities | Initiation | Buy | $6 |
| May 15th 2025 | BTIG Research | Initiation | Buy | $7 |
| February 26th 2024 | Jefferies | Resumed | Buy | $2.5 |
| September 14th 2022 | Guggenheim | Initiation | Buy | $7 |
| August 15th 2022 | Jefferies | Initiation | Buy | $10 |
Earnings History & Surprises
TOIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.14 | $-0.14 | 0.0% | = MET |
Q2 2025 | May 14, 2025 | — | $-0.17 | — | — |
Q1 2025 | Mar 24, 2025 | $-0.08 | $-0.14 | -75.0% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.07 | $-0.18 | -157.1% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.10 | $-0.17 | -70.0% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.12 | $-0.22 | -83.3% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-0.11 | $-0.21 | -90.9% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.13 | $-0.19 | -46.2% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.17 | $-0.19 | -11.8% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.17 | $-0.10 | +41.2% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.16 | $-0.17 | -6.3% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | — | $-0.06 | — | — |
Q2 2022 | May 11, 2022 | — | $-0.29 | — | — |
Q1 2022 | Mar 10, 2022 | — | $0.26 | — | — |
Q4 2021 | Nov 8, 2021 | — | $-0.04 | — | — |
Q3 2021 | Aug 16, 2021 | — | $0.05 | — | — |
Q2 2021 | May 28, 2021 | — | $-0.02 | — | — |
Latest News
Needham Initiates Coverage On Oncology Institute with Buy Rating, Announces Price Target of $5
📈 PositiveThe Oncology Institute shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 sales guidance above estimates.
📈 PositiveThe Oncology Institute shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 sales guidance above estimates.
📈 PositiveOncology Institute Raises FY2025 Sales Guidance from $460.000M-$480.000M to $495.000M-$505.000M vs $474.067M Est
📈 PositiveThe Oncology Institute Q3 EPS $(0.14) Misses $(0.11) Estimate, Sales $136.564M Beat $122.633M Estimate
➖ NeutralAscertain, Oncology Institute Collaborate To Co-Develop Administrative Workforce To Mitigate Manual Interactions Among Players, Providers
📈 PositiveThe Oncology Institute Reports Cyber Incident At IT Vendor Causing Minor Delay In Fee-For-Service Collections; Says No Evidence Of Patient Data Compromise In Incident
➖ NeutralBTIG Reiterates Buy on Oncology Institute, Maintains $7 Price Target
📈 PositiveThe Oncology Institute Reaches $1.1M In Medicare Savings In CMS Enhancing Oncology Model Performance Period 2 Through California Professional Corporation
📈 PositiveThe Oncology Institute Q2 Revenue Surges
📈 PositiveFrequently Asked Questions about TOI
What is TOI's current stock price?
What is the analyst price target for TOI?
What sector is The Oncology Institute, Inc. in?
What is TOI's market cap?
Does TOI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TOI for comparison